- 2012.05.14
-
Summary of Financial Results for the 1Q ended March 31, 2012
- 2012.03.14
-
Composition of Matter Patent for Acid Pump Antagonist Approved in China
- 2012.03.13
-
Business Report for the fourth fiscal year ended December 31, 2011
- 2012.02.29
-
RaQualia to Initiate First-In-Human Study for A Novel 5-HT4 Partial Agonist RQ-00000010
- 2012.02.23
-
Mid-Term Business Plan 2012 - 2014
- 2012.02.16
-
Summary of Business Report for the fourth fiscal year ended December 31, 2011
- 2012.05.07
- RaQualia to Make Presentations at DDW 2012 at San Diego in May
- 2012.04.24
- 5-HT2B Antagonist RQ-00310941 Is Advanced to Pre-clinical Stage
- 2012.02.08
-
Start of Phase II Study of the 2nd Generation (Atypical) Antipsychotic Drug Ziprasidone in Japan
- 2012.01.31
-
Composition of Matter Patent for Acid Pump Antagonist Approved in Korea
- 2011.12.28
- Pharmaceutical Executive Magazine Features RaQualia: December Issue Cover Story Highlights the Company’s Venture Model
- 2011.12.15
- RaQualia Announces Clinical Research Collaboration with Chiba University Hospital
-
A Movie Introducing RaQualia Pharma
-
Simple Keys to Understanding RaQualia Pharma's Business
